Introduction {#Sec1}
============

Cervical carcinogenesis is a multi-step process associated with refractory infection by high-risk human papillomavirus (HPV) types \[[@CR1], [@CR2]\]. This includes the transformation of normal cervical epithelium to cervical intraepithelial neoplasia (CIN), which is transformed to invasive cervical carcinoma \[[@CR1], [@CR2]\]. The HPV oncoproteins E6 and E7 play a key role in cervical carcinogenesis via the disturbance of apoptosis, the cell cycle, and adaptive immune surveillance \[[@CR3]\]. Only a minority of HPV infected women will develop CIN or cervical cancer, suggesting that HPV is not a sufficient separate factor responsible for tumorigenesis of the cervix \[[@CR4]\]. Many epidemiological studies have also indicated that environmental factors, contraceptive use, smoking, and genetic factors may also contribute to cervical carcinogenesis \[[@CR5]--[@CR9]\].

Recently, several studies have demonstrated that HPV infections may change the expression of toll-like receptors (TLRs), which interferes with TLRs signaling during early and late malignant transformation of the cervix \[[@CR10]--[@CR13]\]. TLRs recognize exogenous pathogen-associated molecular patterns and they play an elementary role in the innate immune response \[[@CR14]\].

In humans, the family of TLRs includes ten members, which can be divided based on their localization in the cell \[[@CR14]\]. TLR1, TLR2, TLR4, TLR5, TLR6, and TLR10 are usually situated on the cell surface, whereas TLR3, TLR7, TLR8, and TLR9 are localized almost exclusively in endosomes \[[@CR14]--[@CR17]\]. TLR9 have been shown to recognize unmethylated cytosine--phosphate--guanine (CpG) dinucleotide motifs located in bacterial, viral and fungal DNA \[[@CR17], [@CR18]\]. TLR9 is present in macrophages, dendritic cells and intestinal epithelium, as well as respiratory epithelial and keratinocytes cells [\[]{.ul}[@CR16], [@CR17], [@CR19]--[@CR21][\]]{.ul}. It has been demonstrated that the −1486 T/C (rs187084), −1237T/C (rs5743836) and C2848T (rs352140) polymorphisms of *TLR9* located in the same block of linkage disequilibrium (LD) may change *TLR9* expression (HapMap CEU data <http://hapmap.ncbi.nlm.nih.gov/>) \[[@CR22]--[@CR24]\].

There are two studies on the association of the *TLR9* 1486 T/C (rs187084) and C2848T (rs352140) polymorphisms with cervical cancer in various populations, however, the results are inconsistent \[[@CR25], [@CR26]\]. Therefore, we aimed to study whether *TLR9* −1486 T/C (rs187084) and C2848T (rs352140) can be a genetic risk factor of cervical cancer in the Polish population.

Patients and methods {#Sec2}
====================

Patients and controls {#Sec3}
---------------------

The patient group was composed of 426 women with histologically determined cervical carcinoma according to the International Federation of Gynecology and Obstetrics (FIGO). All women were enrolled between April 2007 and July 2011 at the Department of Radiotherapy, Greater Poland Cancer Center in Poznan, Poland (Table [1](#Tab1){ref-type="table"}). The controls included four hundred sixty unrelated healthy female volunteers who were matched by age to the patients (Table [1](#Tab1){ref-type="table"}). Information about pregnancy, oral contraceptive use, tobacco smoking, and menopausal status was obtained as part of the patient history. Patients and controls were Caucasian, enrolled from the Wielkopolska area of Poland. All subjects provided written informed consent. The study was approved by the Local Ethical Committee of Poznan University of Medical Sciences.Table 1Clinical and demographic characteristics of patients and controlsCharacteristicPatients (*n* = 426) (%)Controls (*n* = 460) (%)^a^Mean age (years) ± SD51.8 ± 9.751.9 ± 9.8Tumor stage IA55 (12.9) IB57 (13.4) IIA56 (13.1) IIB47 (11.0) IIIA143 (33.6) IIIB54 (12.7) IVA8 (1.9) IVB6 (1.4)Histological grade G177 (18.1) G2133 (31.2) G394 (22.1) Gx122 (28.6)Histological type Squamous cell carcinoma361 (84.8) Adenocarcinoma50 (11.7) Other15 (3.5)Pregnancy Never45 (10.6)51 (11.1) Ever381 (89.4)409 (88.9)Oral contraceptive pill use Never234 (54.9)257 (55.9) Ever192 (45.1)203 (44.1)Tobacco smoking Never278 (65.3)312 (67.8) Ever148 (34.7)148 (32.2)Menopausal status Premenopausal149 (35.0)175 (41.1) Postmenopausal277 (65.0)285 (61.9)^a^Age at first diagnosis

Genotyping {#Sec4}
----------

DNA was obtained from peripheral leucocytes using a standard salting out procedure. Identification of the *TLR9* -1486 T/C (rs187084) and C2848T (rs352140) polymorphic variant was performed by polymerase chain reaction-restriction fragment length polymorphism (PCR--RFLP). PCR was conducted employing primer pair 5′TTCATTCATTCAGCCTTCACTCA 3′, 5′ GAGTCAAAGCCACAGTCCACA 3′ and 5′ GCAGCACCCTCAACTTCACC 3′and 5′ GGCTGTGGATGTTGTTGTGG 3′, respectively.

The PCR-amplified fragments 565 bp in length bearing the *TLR9* -1486 T/C (rs187084) polymorphism were digested with restriction enzyme Afl II (C/TTAAG) New England BioLabs, (Ipswich, USA). The *TLR9* T allele was cleaved into 416 and 149 bp fragments, whereas the *TLR9* C allele remained uncut. The PCR-amplified fragments 360 bp in length corresponding to the *TLR9* C2848T polymorphism were subjected to digestion with the endonuclease BstUI (CG/CG) New England BioLabs, (Ipswich, USA). The *TLR9* C allele was cleaved into 227 and 133 bp fragments, whereas the *TLR9* T allele remained uncut. DNA fragments were separated by electrophoresis on 3 % agarose gel and visualized by ethidium bromide staining. The *TLR9* 1486 T/C and C2848T polymorphism was confirmed by repeated PCR--RFLP. Moreover, the restriction analysis was confirmed by commercial sequencing analysis.

Statistical analysis {#Sec5}
--------------------

The distribution of genotypes in patients and controls was examined for deviation from Hardy--Weinberg equilibrium using exact and log likelihood ratio χ^2^ tests \[<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>\]. The polymorphism was tested for association with cervical cancer using the χ^2^ test for trend (p~trend~). The χ^2^ test was employed to examine differences in genotypic and allelic distribution between patients and controls. The odds ratio (OR) and 95 % confidence intervals (95 % CI) were calculated. Unconditional logistic regression analysis was used to adjust for the effect of confounders such as age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status. A *p* value of \<0.05 was considered statistically significant.

Results {#Sec6}
=======

Prevalence of the *TLR9* −1486 T/C polymorphism in women with cervical cancer {#Sec7}
-----------------------------------------------------------------------------

There was a higher frequency of the *TLR9* CC genotype in women with cervical cancer compared to healthy individuals, which was 0.19 and 0.14, respectively (Table [2](#Tab2){ref-type="table"}). We also found increased *TLR9* C/T heterozygote frequency in patients than in controls, which was 0.48 and 0.44, respectively (Table [2](#Tab2){ref-type="table"}). There was also an increased *TLR9* C allele frequency in patients than in controls, which was 0.43 and 0.36, respectively (Table [2](#Tab2){ref-type="table"}). The p value of the χ^2^ test of the trend observed for the *TLR9 −1486 T/C* polymorphism was statistically significant (p~trend~ = 0.0042). Logistic regression analysis showed a significant contribution of the *TLR9 −*1486 T/C polymorphism to cervical cancer (Table [2](#Tab2){ref-type="table"}). The adjusted OR for patients with the C/T genotype vs T/T genotype was 1.371 (95 % CI 1.021--1.842, *p* = 0.0361), the adjusted OR for the C/C genotype vs the T/T genotype was 1.300 (95 % CI 1.016--1.507, *p* = 0.0096), and the adjusted OR for the C/T or C/C genotype vs the T/T genotype was 1.448 (95 % CI 1.099--1.908, *p* = 0.0083) (Table [2](#Tab2){ref-type="table"}).Table 2Contribution of the *TLR9 −*1486 T/C (rs187084) and C2848T (rs352140) polymorphisms to cervical cancerPolymorphismrs no.GenotypePatients (frequency)Controls (frequency)Odds ratio (95 % CI)*p*^a^Adjusted odds ratio (95 % CI)^b^*p*^a^**−1486 T/C**rs187084TT141 (0.33)193 (0.42)Referent--Referent--CT206 (0.48)203 (0.44)1.389 (1.038--1.858)0.0267**1.371 (1.021--1.842)0.0361**CC79 (0.19)64 (0.14)**1.690 (1.138--2.508)0.00891.300 (1.016--1.507)0.0096**CT + CC285 (0.67)267 (0.58)**1.461 (1.111--1.922)0.00661.448 (1.099--1.908)0.0083**Minor allele frequency0.430.36**1.327 (1.096--1.607)0.0037C2848T**rs352140CC87 (0.20)122 (0.27)Referent--Referent--CT230 (0.54)235 (0.51)1.372 (0.987--1.909)0.0594**1.443 (1.019--2.043)0.0380**TT109 (0.26)103 (0.22)**1.484 (1.010--2.181)0.04411.237 (1.016--1.507)0.0328**CT + TT339 (0.80)338 (0.73)**1.406 (1.028--1.925)0.0326**1.345 (0.976--1.855)0.0700Minor allele frequency0.530.481.204 (0.999--1.452)0.0506Significant results are highlighted in bold font^a^χ^2^ analysis^b^ORs were adjusted by age, pregnancy, oral contraceptive use, tobacco smoking, and menopausal status

Prevalence of the *TLR9* C2848T polymorphism in women with cervical cancer {#Sec8}
--------------------------------------------------------------------------

We observed an increased frequency of the *TLR9* TT genotype in patients than controls, which was 0.26 and 0.22, respectively (Table [2](#Tab2){ref-type="table"}). The *TLR9* C/T heterozygote frequency in women with cervical cancer was also increased compared to healthy individuals and amounted to 0.54 and 0.51, respectively (Table [2](#Tab2){ref-type="table"}). We also observed a higher *TLR9* T allele frequency in patients then healthy individuals, which was 0.53 and 0.48, respectively (Table [2](#Tab2){ref-type="table"}). The p value of the χ^2^ test of the trend observed for the *TLR9* C2848T polymorphism was statistically significant (p~trend~ = 0.0449). Logistic regression analysis showed a significant association of the *TLR9* C2848T polymorphism with cervical cancer (Table [2](#Tab2){ref-type="table"}). The adjusted OR for patients with the C/T genotype vs C/C genotype was 1.443 (95 % CI 1.019--2.043, *p* = 0.0380), the adjusted OR for the T/T genotype vs the C/C genotype was 1.237 (95 % CI 1.016--1.507, *p* = 0.0328), and the adjusted OR for the T/C or T/T genotype vs the C/C genotype was 1.345 (95 % CI 0.976--1.855, *p* = 0.0700) (Table [2](#Tab2){ref-type="table"}).

Discussion {#Sec9}
==========

TLR9 plays a crucial role in pathogen recognition and activation of innate immunity \[[@CR15], [@CR18]\]. Stimulation of TLR9 activates human B cells and plasmacytoid dendritic cells, causing T helper-1 type immune responses and antitumor responses \[[@CR18], [@CR27]--[@CR31]\]. The role of the TLR9 pathway in anticancer treatment has been considered in animal models and patients with renal carcinoma, malignant melanoma, and non-Hodgkin's lymphoma \[[@CR27]--[@CR31]\]. Moreover, the significance of the TLR9 pathway has been demonstrated in vaccine treatment of cervical carcinoma in murine model \[[@CR28]\]. Mansilla et al. \[[@CR28]\] demonstrated that intratumoral administration of EDA-HPVE7 fusion protein in combination with TLR9 ligand CpG-B was able to eradicate large established cervical tumors.

HPV infects primitive basal keratinocytes; however, its abundant expression and viral assembly take place only in the upper layers of the stratum spinosum and granulosum of squamous epithelia \[[@CR32]\]. Keratinocytes bear TLR9, and stimulation of TLR9 may result in the production of a spectrum of mediators influencing the function of immune cells \[[@CR21]\]. Some studies have suggested that changes occur in *TLR9* expression during cervical carcinogenesis \[[@CR11], [@CR13]\]. Recently, Hasimu et al. (2007) found that the expression of *TLR9* can be up-regulated by HPV16 infection in CIN and in cervical squamous carcinoma cells \[[@CR11]\]. They also suggested that TLR9 may play important roles in the development and progression of CIN and cervical carcinoma \[[@CR11]\]. Adding to the above findings are those of Hasan et al. \[[@CR13]\], who demonstrated that HPV16 infection of human primary keratinocytes reduced *TLR9* transcription and lead to a functional loss of TLR9-regulated pathways. This may suggest that polymorphisms of *TLR9* that modulate the expression of *TLR9* may have an effect on the etiopathogenesis of cervical cancer \[[@CR33]\].

We observed a contribution of the *TLR9* −1486 T/C (rs187084) and C2848T (rs352140) polymorphisms to the risk of cervical cancer in a Polish population. Recent studies conducted by Chen et al. \[[@CR25]\] demonstrated that the *TLR9* −1486 T/C (rs187084) polymorphism, located in the LD block with rs352140, was associated with a significantly increased risk of cervical cancer. In contrast, Pandey et al. \[[@CR26]\] showed that the TT genotype of *TLR9* (rs352140) displayed borderline significance in increased risk for advanced cervical cancer in a North India population.

These differences in the effect of *TRL9* polymorphism on the susceptibility to cervical cancer development between our and Hindu populations may result from racial heterogeneity, the size of the studied groups, and the action of distinct behavioral and environmental factors \[[@CR33]\].

To date, the *TLR9* C2848T (rs352140) polymorphism has also been associated with Hodgkin's lymphoma, periodontitis, ulcerative colitis, and systemic lupus erythematosus \[[@CR34]--[@CR37]\]. The other *TLR9* variants have also been found to be risk factors of atopic eczema, tuberculosis, *Helicobacter pylori*-induced gastritis, and rheumatoid arthritis \[[@CR38]--[@CR41]\]. Moreover, these *TLR9* variants may influence the clinical course of HIV-1 infection, and the development of endometrial cancer, osteoarthritis, and non-Hodgkin lymphoma \[[@CR42]--[@CR45]\].

The role of the rs352140 polymorphism on *TLR9* expression has been suggested by Kikuchi et al. \[[@CR24]\],who demonstrated that the *TLR9* 2848 TT genotype was associated with a higher expression of *TLR9* and an increased frequency of IgM + B cells. It has been believed that chronic inflammation may lead to cancer development and progression (33). The increased expression of the *TLR9* 2848 T variant in precursor malignant lesion cells combined with infection by various pathogens might support inflammation and cervical cancer development (33).

Our studies suggest that the C2848T (rs352140) polymorphism might be a risk factor of cervical cancer in Polish women. Our genetic evaluation is the first in a Caucasian cohort; therefore this study should be replicated in a larger and independent cohort.
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